1401 PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment

• Lana Kandalaft,
• Yi-Ru Yu,
• Pandelakis Koni,
• Hung-Kai Chen,
• Huey-Wen Hsiao,
• Claudia Lengerke,
• Chin-Hsien Tsai,
• Jaeoh Park

Affiliations

Lana Kandalaft

1University of Lausanne, Lausanne, Switzerland

Yi-Ru Yu

3University of Lausanne, Lausanne, Switzerland

Pandelakis Koni

6Elixiron Immunotherapeutics, Inc., Larkspur, CA, USA

Hung-Kai Chen

4Elixiron Immunotherapeutics, Taipei, Taiwan

Huey-Wen Hsiao

4Elixiron Immunotherapeutics, Taipei, Taiwan

Claudia Lengerke

8University Hospital Tuebingen, Tuebingen, Germany

Chin-Hsien Tsai

1University of Lausanne, Taipei City, Taiwan

Jaeoh Park

5Ludwig Institute for Cancer Research Lausanne Branch, Epalinges, Switzerland